VITASPRING BIOMEDICAL CO., LTD.: 10-Q filed 2022-09-15
What VITASPRING BIOMEDICAL CO., LTD. reported in its quarterly report filed 2022-09-15 (fiscal Q2 2023): 27 published measures, 63 facts as tagged in accession 0001697884-22-000013.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-09-15
- Fiscal period
- fiscal Q2 2023
- Accession
- 0001697884-22-000013 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VITASPRING BIOMEDICAL CO., LTD. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 2,584,708 | USD | |
| At 2022-01-31 | 3,604,073 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 801,630 | USD | |
| At 2022-01-31 | 2,026,534 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 1,783,078 | USD | |
| At 2022-01-31 | 1,577,539 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 21,590 | USD | |
| At 2022-01-31 | 107,212 | USD | |
| At 2021-07-31 | 614,063 | USD | |
| At 2021-01-31 | 45,398 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-05-01 to 2022-07-31 | 144,137 | USD | 92 |
| 2022-02-01 to 2022-07-31 | -132,521 | USD | 181 |
| 2021-05-01 to 2021-07-31 | -250,877 | USD | 92 |
| 2021-02-01 to 2021-07-31 | -425,839 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | 85,622 | USD | 181 |
| 2021-02-01 to 2021-07-31 | -618,450 | USD | 181 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | 1,490,000 | USD | 181 |
| 2021-05-01 to 2021-07-31 | 1,390,400 | USD | 92 |
| 2021-02-01 to 2021-07-31 | 1,924,200 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-07-31 | 49,785 | USD | 181 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-05-01 to 2022-07-31 | 206,520,030 | shares | 92 |
| 2022-02-01 to 2022-07-31 | 206,520,030 | shares | 181 |
| 2021-05-01 to 2021-07-31 | 205,458,941 | shares | 92 |
| 2021-02-01 to 2021-07-31 | 205,438,810 | shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-05-01 to 2022-07-31 | -30,326 | USD | 92 |
| 2022-02-01 to 2022-07-31 | 44,667 | USD | 181 |
| 2021-02-01 to 2021-07-31 | 4,448 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 57,105 | USD | |
| At 2022-01-31 | 64,636 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | 73,018 | USD | 181 |
| 2021-02-01 to 2021-07-31 | 79,127 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-05-01 to 2022-07-31 | -174,513 | USD | 92 |
| 2022-02-01 to 2022-07-31 | 168,616 | USD | 181 |
| 2021-05-01 to 2021-07-31 | 250,877 | USD | 92 |
| 2021-02-01 to 2021-07-31 | 430,287 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 2,141,722 | USD | |
| At 2022-01-31 | 3,061,868 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 506,493 | USD | |
| At 2022-01-31 | 1,737,884 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-01-31 | 1,251,500 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 2,120,132 | USD | |
| At 2022-01-31 | 2,952,022 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | 568,000 | USD | 181 |
| 2021-05-01 to 2021-07-31 | 341,200 | USD | 92 |
| 2021-02-01 to 2021-07-31 | 581,000 | USD | 181 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-05-01 to 2022-07-31 | 174,513 | USD | 92 |
| 2022-02-01 to 2022-07-31 | 399,384 | USD | 181 |
| 2021-05-01 to 2021-07-31 | 90,323 | USD | 92 |
| 2021-02-01 to 2021-07-31 | 150,713 | USD | 181 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 894,603 | USD | |
| At 2022-01-31 | 877,797 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 368,267 | USD | |
| At 2022-01-31 | 459,955 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 99,771 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 11,408 | USD | |
| At 2022-01-31 | 6,181 | USD |
Net deferred tax liabilities
Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-07-31 | 11,408 | USD | |
| At 2022-01-31 | 6,181 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | -39,440 | USD | 181 |
| 2021-02-01 to 2022-01-31 | -210,923 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-02-01 to 2022-07-31 | 7,531 | USD | 181 |
| 2021-02-01 to 2021-07-31 | 830 | USD | 181 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-07-31 | 144,000 | USD | 181 |
Inspect the source
- Entity
- VITASPRING BIOMEDICAL CO., LTD. / CIK 0001697884
- Captured
- 2026-09-21T17:23:44.772Z
- SEC response SHA-256
ee15de6dda3aedafc6c6b7ee7d9d21edb5e0091bf01dcbaec55b3fe460e6f43a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001697884.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))